Fig. 1: Risk of Anaphylaxis Following XBB.1.5-containing COVID-19 mRNA Vaccination, Adjusted for COVID-19 Infection and Temporal Trends. | Nature Communications

Fig. 1: Risk of Anaphylaxis Following XBB.1.5-containing COVID-19 mRNA Vaccination, Adjusted for COVID-19 Infection and Temporal Trends.

From: Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study

Fig. 1

Notes: Anaphylaxis was studied separately. Event counts fewer than 20 were replaced with “< 20” in accordance with N3C regulation. IRR indicates incidence rate ratio, calculated using conditional Poisson regression. The primary analysis included patients who received either brand of the XBB.1.5-containing COVID-19 mRNA vaccine and experienced anaphylaxis. The model was adjusted for COVID-19 infection and temporal trends.

Back to article page